Market revenue in 2021 | USD 14.4 million |
Market revenue in 2032 | USD 89.7 million |
Growth rate | 18.1% (CAGR from 2021 to 2032) |
Largest segment | Chronic immunomodulators |
Fastest growing segment | Monoclonal Antibodies |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy |
Key market players worldwide | AstraZeneca PLC, Grifols SA Ordinary Shares - Class A, Avadel Pharmaceuticals PLC, Novartis AG ADR, Pfizer Inc, AbbVie Inc, Roche Holding AG, GlaxoSmithKline, Bausch Health Companies Inc, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to myasthenia gravis treatment market will help companies and investors design strategic landscapes.
Chronic immunomodulators was the largest segment with a revenue share of 31.25% in 2021. Horizon Databook has segmented the India myasthenia gravis treatment market based on cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy covering the revenue growth of each sub-segment from 2018 to 2032.
Presence of a large target population and increasing public-private initiatives to improve access to better treatment therapies are anticipated be major factors supporting market growth in the country. In addition, rising geriatric population and increasing risk of MG in this population group are anticipated to support market growth in the country.
According to a study published by Indian Journal of Ophthalmology, in India, MG is more prevalent in men than in women; the age of onset in men is in the sixth to seventh decade, and that in women is in the third decade.
According to a study published by NCBI, in January 2021, during COVID 19 pandemic, patients suffering from MG were associated with impaired activity of daily living, poor quality of life, & poor sleep quality.
Horizon Databook provides a detailed overview of country-level data and insights on the India myasthenia gravis treatment market , including forecasts for subscribers. This country databook contains high-level insights into India myasthenia gravis treatment market from 2018 to 2032, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account